PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Mesna

Drugs in development · updated 30 October 2026

Mesna: clinical trials and development status

Other names and codes: Uromitexan, Mesnex

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Mesna is in 38 active clinical trials (recruiting or ongoing, phases I–III) for 72 diseases. The most advanced phase is III.

38Active trials
IIIMost advanced phase
72Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Mesna and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 72 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Precursor lymphoblastic lymphoma/leukemiaII11NCT03849651
Acute myeloid leukemiaII8NCT03849651
Hematologic neoplasmI–II6NCT05436418
LymphomaII5NCT02106988
Myelodysplastic SyndromesII5NCT03849651
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveII4NCT03849651
NeoplasmII4NCT06001385
B-cell leukemiaII3NCT06001385
Immune System DiseasesII3NCT06001385
LeukemiaII3NCT06001385
Lymphoid leukemiaII3NCT06001385
Lymphoproliferative disordersII3NCT06001385
MelanomaII3NCT00338377
Non-Hodgkin lymphomaII3NCT03849651
Acute biphenotypic leukaemiaII2NCT06001385
Bone marrow diseaseII2NCT06001385
Chronic lymphocytic leukemiaII2NCT06001385
Crohn's diseaseI–II2NCT04224558
Germ cell and embryonal neoplasmsII2NCT01873326
Hematologic DiseasesII2NCT06001385
Immunoproliferative disorderII2NCT06001385
Juvenile myelomonocytic leukemiaII2NCT03849651
Lymphatic system diseaseII2NCT06001385
MyelofibrosisII2NCT06345495
Myeloid leukemiaII2NCT06001385
OsteosarcomaII2NCT07428993
Precancerous ConditionsII2NCT06001385
PreleukemiaII2NCT06001385
Aplastic anemiaII1NCT04558736
Autoimmune diseaseII1NCT03663933

Everything on Mesna

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch